Filtered By:
Source: American Heart Journal

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 491 results found since Jan 2013.

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Catherine M. Viscoli , Lawrence M. Brass , Antonio Carolei , Robin Conwit , Gary A. Ford , Karen L. Furie , Mark Gorman , Peter D. Guarino , Silvio E. Inzucchi , Anne M. Lovejoy , Mark W. Parsons , Peter N. Peduzzi , Peter A. Ringleb , Gregory G. Schwartz , J. David Spence , David Tanne , Lawrence H. Young , Walter N. Kernan Background Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based o...
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis
Conclusion Our meta-analysis revealed a trend for a reduction of the risk of ischemic stroke in hemodialysis patients with AF treated with VKA. The true protective effect may have been underestimated, owing to inclusion of low-risk patients not expected to benefit from anticoagulation and to suboptimal anticoagulation. However, assessment of the overall effect of VKA in hemodialysis patients should also take into account the increased risk of bleeding, in particular of hemorrhagic stroke. Whether new oral anticoagulants provide a better benefit–risk ratio in hemodialysis patients should be the subject of future trials.
Source: American Heart Journal - October 4, 2016 Category: Cardiology Source Type: research

System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA--a cluster-randomized controlled trial
This study aims to develop a system-integrated technology-enabled intervention model of care (SINEMA) for the secondary prevention of stroke in rural China and to evaluate the effectiveness of the model compared with usual care.MethodsThe SINEMA model is being implemented and evaluated through a one-year cluster-randomized controlled trial in Nanhe County, Hebei Province in China. Fifty villages from five townships are randomized in a 1:1 ratio to either the intervention or the control arm (usual care) with a target to enroll 25 stroke survivors per village. Village doctors in the intervention arm 1) receive systematic cas...
Source: American Heart Journal - September 5, 2018 Category: Cardiology Source Type: research

Atrial fibrillation detected by continuous ECG monitoring using implantable loop recorder to prevent stroke in individuals at risk (The LOOP study): Rationale and design of a large randomized controlled trial
Conclusion The LOOP study will evaluate health benefits and cost-effectiveness of ILR as a screening tool for AF to prevent stroke in patients at risk. Secondary objectives include identification of risk factors for the development of AF and characterization of arrhythmias in the population. The trial holds the potential to influence the future of stroke prevention.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research

Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial
Conclusion The LOOP study will evaluate health benefits and cost-effectiveness of ILR as a screening tool for AF to prevent stroke in patients at risk. Secondary objectives include identification of risk factors for the development of AF and characterization of arrhythmias in the population. The trial holds the potential to influence the future of stroke prevention.
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research

Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) Randomized Trial: Design and Rationale
Conclusion This trial will provide information on the value of ICMs to detect subclinical AF in patients with stroke presumed due to large vessel atherosclerosis or small vessel disease, which will have implications for guiding treatment with oral anticoagulation for secondary stroke prevention.
Source: American Heart Journal - April 19, 2017 Category: Cardiology Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

C-reactive Protein and Stroke Risk in Blacks and Whites: the REasons for Geographic and Racial Differences in Stroke Cohort
ConclusionsCRP may not be equally useful in stroke risk assessment in blacks and whites. Confirmation, similar study for coronary heart disease, and identification of reasons for these racial differences require further study.
Source: American Heart Journal - August 13, 2019 Category: Cardiology Source Type: research

Female Sex is Associated with a Lower Risk of Stroke in Patients with Heart Failure
Conclusions We found an association between female sex and decreased stroke risk in heart failure patients which persisted after adjustment for concomitant cardiovascular risk factors. The association was attenuated with increasing age, possibly due to competing risks of death.
Source: American Heart Journal - December 18, 2014 Category: Cardiology Source Type: research

Blood Pressure Control and Stroke or Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation: Results from the ROCKET AF Trial
Conclusions In a trial of anticoagulated patients with AF, increasing screening SBP was independently associated with stroke and SE, and one-third of patients had uncontrolled hypertension. The relative effectiveness and safety of rivaroxaban versus warfarin was consistent across all levels of screening SBP. A single SBP may be an important factor in reducing the overall risk of stroke and SE in anticoagulated patients with AF.
Source: American Heart Journal - May 6, 2016 Category: Cardiology Source Type: research

How Well Does Physician Risk Assessment Predict Stroke and Bleeding in Atrial Fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Conclusion Physician-assigned risk showed a graded relationship with outcomes and both physician-based and empirical scores yielded only moderate discrimination. While empirical scores provided valuable risk stratification information (with or without physician judgement), physician-assessment added little to existing scores. These data support the use of empirical scores for stroke and bleeding risk stratification, and the need for novel approaches to risk stratification in this population.
Source: American Heart Journal - August 26, 2016 Category: Cardiology Source Type: research

Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial
Conclusions Chronic anemia is associated with a higher incidence of bleeding complications and mortality, but not of stroke, in anticoagulated patients with AF. Apixaban is an attractive anticoagulant for stroke prevention in patients with AF with or without anemia.
Source: American Heart Journal - December 21, 2016 Category: Cardiology Source Type: research

Rationale, design and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS) – a large-scale cluster randomized controlled trial
Publication date: Available online 14 March 2017 Source:American Heart Journal Author(s): Bruce Neal, Maoyi Tian, Nicole Li, Paul Elliott, Lijing L. Yan, Darwin R. Labarthe, Liping Huang, Xuejun Yin, Zhixin Hao, Sandrine Stepien, Jingpu Shi, Xiangxian Feng, Jianxin Zhang, Yuhong Zhang, Ruijuan Zhang, Yangfeng Wu Lowering sodium intake with a reduced-sodium, added potassium salt substitute has been proved to lower blood pressure levels. Whether the same strategy will also reduce the risks of vascular outcomes is uncertain and controversial. The Salt Substitute and Stroke Study (SSaSS) has been designed to test whether sodi...
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research

Factors Associated with Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with New-Onset Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists and had higher socioeconomic status. Trial Registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 4, 2017 Category: Cardiology Source Type: research

Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: GLORIA-AF Registry
Conclusions These global data confirm the sustained safety and effectiveness of dabigatran over 2years of follow-up, consistent with the results from clinical trials as well as contemporary real-world studies. WHAT IS KNOWN • Non- vitamin K antagonist (VKA) anticoagulants (NOACs) are the preferred therapy for prevention of ischemic stroke based on phase 3 trials, but there is insufficient information on their efficacy and safety in daily practice, based on prospectively collected data WHAT IS NEW • This study shows that in non-valvular AF patient population, with up to 2years of follow-up, the use of dabigatran led to ...
Source: American Heart Journal - September 1, 2017 Category: Cardiology Source Type: research